130O - Real-world prevalence of PD-L1 expression in locally advanced or metastatic non-small cell lung cancer (NSCLC): The global, multicentre EXPRESS study

Date 12 April 2018
Event ELCC 2018 European Lung Cancer Congress
Session PD-L1 expression and tumor microenvironment in advanced lung cancer
Topics Non-Small-Cell Lung Cancer, Metastatic
Cancer Immunology and Immunotherapy
Lung and other Thoracic Tumours
Presenter Manfred Dietel
Citation Journal of Thoracic Oncology (2018) 13 (supp_4): S1-S139.
Authors M. Dietel1, N. Savelov2, R. Salanova3, P. Micke4, G. Bigras5, T. Hida6, B. Piperdi7, T. Burke7, S. Khambata-Ford7, A. Deitz7
  • 1Institute Of Pathology, Charite Berlin Mitte, 10117 - Berlin/DE
  • 2Moscow Oncology Hospital, Moscow/RU
  • 3Hospital de Gastroenterología Dr. Carlos Bonorino Udaondo, Buenos Aires/AR
  • 4Department Of Immunology, Genetics And Pathology, Uppsala University, Uppsala/SE
  • 5Cross Cancer Institute, University of Alberta, Edmonton/CA
  • 6Department Of Thoracic Oncology, Aichi Cancer Center, Nagoya/JP
  • 7Merck & Co., Inc., Kenilworth/US

Abstract

PD-L1 expression on tumour cells has been associated with improved clinical benefit from immunotherapies targeting the PD-1 pathway. We conducted a global, multicentre, retrospective observational study to determine real-world prevalence of tumour PD-L1 expression in patients with advanced NSCLC.